Sound waves vs. prostate cancer: new trial aims to zap tumors without surgery

NCT ID NCT05438563

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This Mayo Clinic trial is testing a procedure called MRI-guided TULSA for men with low to intermediate grade prostate cancer. It uses high-energy sound waves guided by MRI to precisely destroy tumor cells, aiming to avoid surgery or radiation. The study will enroll 100 men aged 45-80 and track how well the treatment controls cancer while preserving urinary and sexual function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI-guided transurethral ultrasound ablation (TULSA)
What this could lead to: If successful, this could offer a minimally invasive alternative to surgery or radiation for certain prostate cancers, potentially preserving quality of life.
What could go wrong: This is an early-stage trial with only 100 participants. It may not work for all patients, and risks include treatment failure, side effects, or need for additional therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CARCINOMA STAGE I PROSTATE CANCER AJCC V8 STAGE II PROSTATE CANCER AJCC V8

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.